Figure Legends
Figure 1. A–E, Computed tomography (CT) scans and their date
of examination.
A, Original tumor site. B, Metastasis to the
peritoneal lymph node. C, Relapsed site (right kidney).D, CT findings before vaccination (no tumor). E, The
latest CT findings (no tumor). Arrows indicate the location of the
tumors. F, Immune response for vaccinated peptides. Arrows
indicate the day of vaccination. “20XX” is the year of the first
disease onset. G, Statistical analysis with the 2-fold Wilcoxon
test.
Table 1: Abbreviation; VAC: vincristine, actinomycin D, cyclophosphamide
chemotherapy, ICE: Ifosphamide, Carboplatin, Etoposide chemotherapy,
IMRT: Intensity modulated radiation therapy, DXR: doxorubicin, MTX:
methotrexate, IFO: ifosphamide, CDDP: cisplatinum, VDC: vincristine,
doxorubicin, cyclophosphamide chemotherapy, IE: ifosphamide, etoposide
chemotherapy, DD4A: d-actinomycin, doxorubicin, vincristine
chemotherapy, PTK: Protein tyrosine kinases, TMZ: temozolomide, SD:
stable disease, PD: progressive disease, OS: overall survival
Supplemental table 1: a: A3family, HLA-A3, A11, A31, and A33
Abbreviation: HLA, human leukocyte antgen ; TAA, tumor associated
antigen
Supplemental table 2: Bold number indicated the selected peptide for
vaccination